The estimated Net Worth of Daniel A. Peisert is at least $1.71 Milione dollars as of 11 September 2023. Mr Peisert owns over 158,402 units of Assertio stock worth over $412,673 and over the last 4 years he sold ASRT stock worth over $693,140. In addition, he makes $609,112 as Pres e CEO & Director at Assertio.
Mr has made over 19 trades of the Assertio stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 158,402 units of ASRT stock worth $479,958 on 11 September 2023.
The largest trade he's ever made was exercising 552,067 units of Assertio stock on 12 May 2023 worth over $701,125. On average, Mr trades about 65,882 units every 51 days since 2020. As of 11 September 2023 he still owns at least 324,939 units of Assertio stock.
You can see the complete history of Mr Peisert stock trades at the bottom of the page.
Daniel A. Peisert is the Pres, CEO & Director at Assertio.
As the Pres e CEO & Director of Assertio, the total compensation of Mr Peisert at Assertio is $609,112. There are no executives at Assertio getting paid more.
Mr Peisert is 46, he's been the Pres e CEO & Director of Assertio since . There are 1 older and 1 younger executives at Assertio. The oldest executive at Assertio Holdings, Inc. is Paul Schwichtenberg, 50, who is the Sr. VP & CFO.
Daniel's mailing address filed with the SEC is ASSERTIO HOLDINGS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST, IL, 60045.
Over the last 4 years, insiders at Assertio have traded over $6,616,337 worth of Assertio stock and bought 68,828 units worth $87,071 . The most active insiders traders include Group L.P.Crg Partners Iii ..., Timothy P Walbert e Daniel A. Peisert. On average, Assertio executives and independent directors trade stock every 21 days with the average trade being worth of $278,566. The most recent stock trade was executed by Jeff L Vacirca on 11 June 2024, trading 10,000 units of ASRT stock currently worth $11,100.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Assertio executives and other stock owners filed with the SEC include: